

# 1 Association between vaccination rates and COVID-19 health outcomes in the 2 United States: a population-level statistical analysis 3

4 Hongru Du MS<sup>1,2,\*</sup>, Samee Saiyed MSE<sup>1,2</sup>, and Lauren M. Gardner PhD<sup>1,2,3</sup>  
5

6 <sup>1</sup> Center for Systems Science and Engineering, Johns Hopkins University, Baltimore, MD 21218, USA.

7 <sup>2</sup> Department of Civil and Systems Engineering, Johns Hopkins University, Baltimore, MD 21218, USA.

8 <sup>3</sup> Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, 21205,  
9 USA.

10 \*Corresponding author. Johns Hopkins University, 3400 N. Charles Street, Shaffer 4, Baltimore, MD, 21218,  
11 USA. E-mail address: hdu9@jhu.edu (Hongru Du)

## 12 13 Abstract

14 Population-level vaccine efficacy is a critical component of understanding COVID-19 risk,  
15 informing public health policy, and mitigating disease impacts. Unlike individual-level clinical  
16 trials, population-level analysis characterizes how well vaccines worked in the face of real-world  
17 challenges like emerging variants, differing mobility patterns, and policy changes. In this study,  
18 we analyze the association between time-dependent vaccination rates and COVID-19 health  
19 outcomes for 48 U.S. states. We primarily focus on case-hospitalization risk (CHR) as the  
20 outcome of interest, using it as a population-level proxy for disease burden on healthcare systems.  
21 Performing the analysis using Generalized Additive Models (GAMs) allowed us to incorporate  
22 real-world nonlinearities and control for critical dynamic (time-changing) and static (temporally  
23 constant) factors. Dynamic factors include testing rates, activity-related engagement levels in the  
24 population, underlying population immunity, and policy. Static factors incorporate comorbidities,  
25 social vulnerability, race, and state healthcare expenditures. We used SARS-CoV-2 genomic  
26 surveillance data to model the different COVID-19 variant-driven waves separately, and evaluate  
27 if there is a changing role of the potential drivers of health outcomes across waves. Our study  
28 revealed a strong and statistically significant negative association between vaccine uptake and  
29 COVID-19 CHR across each variant wave, with boosters providing additional protection during  
30 the Omicron wave. Higher underlying population immunity is shown to be associated with  
31 reduced COVID-19 CHR. Additionally, more stringent government policies are generally  
32 associated with decreased CHR. However, the impact of activity-related engagement levels on  
33 COVID-19 health outcomes varied across different waves. Regarding static variables, the social  
34 vulnerability index consistently exhibits positive associations with CHR, while Medicaid  
35 spending per person consistently shows a negative association. However, the impacts of other  
36 static factors vary in magnitude and significance across different waves. This study concludes  
37 that despite the emergence of new variants, vaccines remain highly correlated with reduced

38 COVID-19 harm. Therefore, given the ongoing threat posed by COVID-19, vaccines remain a  
39 critical line of defense for protecting the public and reducing the burden on healthcare systems.

40  
41 **Keywords:** COVID-19, vaccination rates, population-level, United States, statistical analysis

## 44 1. Background

45 By March 1<sup>st</sup>, 2023, the COVID-19 pandemic caused over 102 million reported cases and 1.1  
46 million deaths in the United States. Vaccine development and distribution have been at the  
47 forefront of efforts to combat the impact of the disease. Three vaccines are currently available in  
48 the U.S., developed by Pfizer-BioNTech, Moderna, and Johnson & Johnson. Initial randomized  
49 clinical trials demonstrated the safety and efficacy of these vaccines, with vaccine efficacies  
50 against severe disease (hospitalization and death) ranging from 73.1% to 96.7% [1–3]. The  
51 clinical trials were designed to estimate the direct effect of vaccines against severe disease at the  
52 individual level [4]. However, as vaccines roll out to a broader population, uncertainties such as  
53 the emergence of new variants, variable immune responses, the quality of cold-chain storage, and  
54 other confounding factors can impact a vaccine's efficacy [5]. Hence, evaluating real-world  
55 vaccine protection against COVID-19 health outcomes poses a challenge.

56 Several published studies have attempted to quantify the real-world impact of the COVID-19  
57 vaccines on health outcomes. For example, a study in Qatar assessed the vaccines' effectiveness  
58 against severe, critical, or fatal Omicron infections using test-negative case-control analysis, and  
59 found previous infections and vaccination are effective against symptomatic Omicron infections  
60 [6]. An observational study conducted in Israel using national surveillance data showed that the  
61 two doses of the Pfizer-BioNTech mRNA vaccines are 97.2% effective in preventing COVID-  
62 19-related hospitalizations [7]. A Danish study estimated vaccine effectiveness against COVID-  
63 19 hospitalization using a cohort study design, and found that two doses of the vaccine provide  
64 high protection against hospitalization for the Alpha and Delta variant, and even higher  
65 protection against hospitalization for the Omicron variant [8]. A similar cohort study was applied  
66 in Singapore and the United Kingdom to determine whether booster shots reduce the severity of  
67 COVID-19 infections during the Omicron wave, and found consistent results that the risk of  
68 severe COVID-19 outcomes reduced after receiving booster mRNA vaccines [9,10].

69 Most existing literature on the population-level effects of COVID-19 vaccination is based on  
70 individual-level data and observational studies. Specifically, these studies relied upon detailed  
71 individual-level data to assess the direct effectiveness of vaccination by comparing health  
72 outcomes between vaccinated and unvaccinated individuals exposed to the same environment.  
73 However, these studies may be subject to confounding by unmeasured factors and inconsistent  
74 quality of individual-level data. Further, in the U.S., such high-resolution data is unavailable at  
75 the population-level, so alternative strategies must be engaged to evaluate the impact of vaccine  
76 at a regional level.

77 One such approach is to rely on compartmental and agent-based models to simulate transmission  
78 and disease outcomes both in the presence and absence of vaccines implementation for the same

79 population. Watson et al applied this method to estimate the impact of varying vaccine uptake  
80 rates on mortality across multiple countries and found that vaccines prevented 14.4 million  
81 COVID-19 deaths in 2021 [11]. However, this approach is subject to many assumptions and is  
82 limited in its ability to estimate accurate effectiveness. Alternatively, statistical methods such as  
83 time series and regression analysis can be implemented to evaluate the association between  
84 vaccination coverage and healthcare outcomes across different locations. One study using this  
85 strategy evaluated the association between vaccination coverage and the COVID-19 cases  
86 growth rate for all 50 U.S. states in the U.S. using a structural nested mean model and found a 1%  
87 increase in vaccination coverage was associated with a 1.02% reduction in case growth rate [12].  
88 However, the scope of this study is limited to cases between March and May 2021. Another  
89 study utilized linear regression to analyze vaccine coverage and natural immunity in relation to  
90 mortality during the Delta and Omicron waves. It found that vaccine coverage reduced COVID-  
91 19 mortality, but seroprevalence and prior infection rates were not associated with mortality [13].  
92 However, this method has limitations in capturing dynamic changes and non-linear relationships  
93 between variables. A different study by Bollyky et al [14] applied regression analysis to  
94 determine how vaccination coverage amongst other factors (e.g., presence of comorbidities,  
95 political partisanship, race, and ethnicity) impacted health outcomes (standardized infections and  
96 deaths) in the U.S. at the state level, and determined that higher vaccination rates were associated  
97 with lower death rates. The scope of this study varies from ours in its focus on the association  
98 between static variables and COVID-19 health outcomes for a fixed time window between  
99 January 1<sup>st</sup>, 2020, and July 31<sup>st</sup>, 2022, while our study expands the analysis by incorporating  
100 novel dynamic variables to capture behavioral changes over time, and explicitly evaluating the  
101 different variants independently. A recent study evaluated the time-varying relationship between  
102 vaccination, mobility, and COVID-19 health outcomes before and after the Omicron waves [15].  
103 They found the significance of the vaccine's impact in reducing case rates diminished during the  
104 Omicron surge, while its efficacy in lowering case-fatality rates remained substantial throughout  
105 the pandemic.

106 Our study contributes to the existing literature by prioritizing case-hospitalization risk as the  
107 outcome variable, breaking aggregated mobility into activity-related engagement levels,  
108 modeling previous infections as a dynamic variable, including an interaction between the  
109 completed primary series and booster rate for the Omicron wave, and considering the critical  
110 static factors such as comorbidities, social vulnerability, race, and state healthcare expenditures.  
111 Despite numerous studies assessing the effectiveness of vaccines, most have not accounted for  
112 the relative impact of vaccines across different populations and variant waves, while considering  
113 dynamic potential confounding factors. Therefore, a more comprehensive understanding of  
114 vaccines' impact across diverse populations and COVID-19 waves is crucial in developing  
115 informed public health policies that can effectively mitigate the spread of the virus and ensure  
116 equitable distribution of healthcare resources.

117

## 118 **2. Methods**

### 119 **2.1 Study design**

120 The primary objective of this study is to analyze the association between COVID-19 vaccination  
121 rates and COVID-19 case-hospitalization risk (CHR) in the U.S. while controlling for potential  
122 confounding effects. Time-dependent COVID-19 CHR is chosen as the modeled response  
123 variable to gain insights into the factors influencing COVID-19 harm; CHR serves as both a  
124 proxy for disease severity at an individual level, and captures the burden on the healthcare  
125 system at a population level. We use Generalized Additive Models (GAMs) to perform the  
126 analysis because of their ability to capture nonlinear dynamics. Data used include novel dynamic  
127 covariates that may potentially contribute to COVID-19 CHR, such as naturally derived  
128 immunity from prior COVID-19 infection, local healthcare infrastructure, activity-related  
129 engagement levels in the population, and government policies, alongside various static variables  
130 that have been identified to be significant in previous studies [14,16,17] such as comorbidities,  
131 social vulnerability index (SVI), race, and state healthcare expenditures. By controlling for these  
132 factors, we aim to provide a more comprehensive understanding of the association between  
133 vaccination rate and COVID-19 CHR at the population level. To further elucidate the role of  
134 potential driving factors, we also model reported case incidence rates (CIR) as a separate  
135 response variable and compared the factors associated with COVID-19 transmission versus those  
136 associated with COVID-19 CHR. Our framework explicitly captures the spatial variation in the  
137 modeled relative associations through a variable transformation procedure (discussed in detail in  
138 the methods section). The study was conducted for 48 states in the U.S. for the period between  
139 April 19<sup>th</sup>, 2021, the date at which the vaccines were approved for all adults in the U.S., to March  
140 1<sup>st</sup>, 2022. This period covers the pre-Delta (characterized by the predominance of the Alpha  
141 variant and other variants), Delta, and Omicron waves of COVID-19, which are each evaluated  
142 independently. To distinguish between COVID-19 variant-driven waves, we utilized SARS-  
143 CoV-2 genomic surveillance data and identified the dominant variant for each state and point in  
144 time, to determine time windows so the distinct variant-driven waves can be modeled  
145 independently. For the Omicron wave, we also considered the added benefit of booster doses on  
146 COVID-19 health outcomes. Specifically, we evaluated the interaction between the completed  
147 primary series and booster rate on reducing COVID-19 CHR. Results from this analysis help  
148 improve our understanding of the real-world relative impact of the available COVID-19 vaccines  
149 against COVID-19 CHR at the population-level over time, and can help inform future public  
150 health policies to reduce harm.

151

### 152 **2.2 Data sources and collection**

153 We collected state-level time-series data and static variables from publicly available databases.  
154 All time-series data were aggregated to the weekly level. A summary of the variables and their  
155 respective sources are listed in Table 1, and detailed explanations of each variable are provided  
156 in Appendix section 1.2. A 3-week moving average was applied to all time-series variables to  
157 mitigate the effects of potential noise and reporting issues, with the exception of the government  
158 policy index.

159

160 Table 1. Summary of dynamic variables in the model.

| Variable Name                      | Variable Description  | Source     |
|------------------------------------|---|------------|
| <b>Output variables</b>            |   |            |
| Case-hospitalization rate (CHR)    | Weekly new admissions of patient with confirmed COVID-19 normalized by reported cases for each state.   | [18], [19] |
| Reported case-incidence rate (CIR) | Weekly number of confirmed cases normalized by state population.  | [18]       |
| <b>Dynamic input variables</b>     |   |            |
| Partial vaccination rate           | Percentage of the total population that received at least one dose of COVID-19 vaccine approved or authorized for use in the United States.   | [20]       |
| Completed primary series rate      | Percentage of the population that received the second dose in a two-dose COVID-19 vaccines primary series or one dose of a single-dose COVID-19 vaccine primary series approved or authorized for use in the United States. | [20]       |
| Booster vaccination rate           | Percentage of the total population that received an updated (bivalent) booster dose.  | [21]       |
| Weekly testing rate                | Total number of weekly tests conducted for each state normalized by population.   | [22]       |
| Gym visits                         | Number of weekly visits to gyms per person.   | [23,24]    |
| University visits                  | Number of weekly visits to universities per person.   | [23,24]    |
| Physician visits                   | Number of weekly visits to physicians per person.   | [23,24]    |
| Government policy index            | Quantitative measure of government policies implemented in response to the COVID-19 pandemic across various domains including health, social, and economic policies.  | [25]       |
| Previous infections                | Infections reported within a time window preceding the modeled output, e.g., sum from 4 to 16 weeks ahead of the output variables.  | [18]       |

161

162

163 Table 2. Summary of static variables in the model.

| Static input variables           | Description   | Mean  | St.d. | Min   | Max   | Source |
|----------------------------------|---|-------|-------|-------|-------|--------|
| Black proportion                 | The proportion of the population identified as Black.   | 0.112 | 0.019 | 0.006 | 0.378 | [26]   |
| Social vulnerability index (SVI) | The Social Vulnerability Index utilizes data from the U.S. Census to assess the relative level of social vulnerability in each census tract. By analyzing 14 social factors, the SVI categorizes tracts into four closely interrelated themes and then aggregates them as a single indicator of social vulnerability. | 0.468 | 0.152 | 0.137 | 0.771 | [27]   |
| Adults at high risk              | The proportion of the population over 18 years old is at high risk of serious illness if infected with Coronavirus.   | 0.383 | 0.036 | 0.300 | 0.493 | [28]   |
| Medicaid spending                | Total Medicaid spending in thousands of dollars for each state normalized by the population.  | 1.807 | 0.550 | 0.860 | 3.099 | [29]   |

164

### 165 *2.3 Dynamic variable transformation*

166 To ensure the precise estimation of each dynamic variable's impact, a variable transformation  
 167 mechanism must be used to account for the effects of time trends in the data. For example, the  
 168 completed primary series rate is always increasing with time for all locations modeled, hence it  
 169 can be difficult to distinguish how much of the observed associations between vaccination rate  
 170 and COVID-19 health outcomes are due to the variable interaction or the passage of time.  
 171 Moreover, the main focus of this study lies in modeling spatial differences and considering  
 172 location-specific variations that influence the observed associations. Consequently, we applied  
 173 the following transformation to all dynamic variables to remove the time trend and redefine the  
 174 relative variable ( $RV_i^t$ ):



$$RV_i^t = \frac{V_i^t}{\frac{1}{n} \sum_j V_j^t}$$

175 Where  $RV_i^t$  represents the transformed variable for state  $i$  at week  $t$ ,  $V_i^t$  represents the original  
176 variable for state  $i$  at week  $t$  without the transformation,  $\frac{1}{n} \sum_j V_j^t$  represents the mean of the  
177 original variable at week  $t$ , over all locations being modeled  $n$ , e.g., the national mean across the  
178 U.S. A  $RV_i^t$  larger than one indicates that state  $i$  has a higher variable value compared to the  
179 national mean at week  $t$ , while  $RV_i^t$  lower than one indicates that state  $i$  has a lower variable  
180 value compared to the national mean, at week  $t$ . After normalization, the final set of time-  
181 dependent variables included in the analysis are: Relative case-hospitalization rates ( $RCHR_i^t$ ),  
182 relative reported case-incidence rate ( $RCIR_i^t$ ), relative completed primary series rate ( $RCPSR_i^t$ ),  
183 relative booster rate ( $RBR_i^t$ ), relative weekly testing rate ( $RWTR_i^t$ ), relative gym visits ( $RGV_i^t$ ),  
184 relative physician visits ( $RPV_i^t$ ), relative university visits ( $RUV_i^t$ ), relative previous infection  
185 ( $RPI_i^t$ ), and relative government policy ( $RGP_i^t$ ). These newly transformed variables enable an  
186 explicit evaluation of the relative association between each of them and the COVID-19 health  
187 outcome of interest within a single multi-state model. Moreover, this variable transformation  
188 procedure facilitates assessing individual state's performance relative to national dynamics. It  
189 emphasizes evaluating the expected outcomes when a state's performance diverges from the  
190 national average.

191 The dynamic variables, with and without variable transformation, are visually depicted in  
192 Appendix figure S2. Among all the variables, the rankings of  $RCPSR_i^t$  remain relatively stable  
193 across time, as seen in Appendix figure S2b2. This stability indicates a more consistent spatial-  
194 temporal pattern of variation among vaccination rates across states. On the other hand, all other  
195 dynamic variables exhibit more noticeable spatial ranking changes over time. The changing  
196 spatial-temporal rankings of other dynamic variables highlight the importance of considering  
197 spatial differences through time and evaluating their influence on COVID-19 health outcomes.

## 198 **2.4 Statistical analysis**

199 The generalized additive model (GAM) was selected as the statistical model for this analysis  
200 because of its ability to capture complex and nonlinear relationships between the set of  
201 covariates and the outcome variables of interest in each state. We independently model each  
202 variant-driven wave during the study period to allow for different driving factors for different  
203 variants. To define the variant waves, we clustered each state-week pair based on the dominant  
204 circulating variant based on SARS-CoV-2 genomic surveillance data downloaded from GISAID  
205 [30]. The three waves are classified as: 1) Pre-Delta Wave, 2) Delta Wave, 3) Omicron Wave,  
206 and each state is labeled with its most dominant variant each week to define the windows.  
207 Details of this classification are described in Appendix section 1.1, and the assignment of state-  
208 week pairs is shown in Appendix figure S1.

209 The primary set of models treat weekly state-level RCHR as the response variable, with separate  
210 models generated independently for each variant wave, namely Pre-Delta-RCHR, Delta-RCHR,  
211 and Omicron-RCHR. These three models have the form:

212

$$\begin{aligned}
 RCHR_i^t &\sim \text{Gamma}(\mu, \phi) \\
 \log(\mu) &= \alpha + f_1(RCPSR_i^{t-2}) + f_2(RWTR_i^{t-2}) + f_3(RGV_i^{t-2}) + f_4(RPV_i^{t-2}) \\
 &+ f_5(RUV_i^{t-2}) + f_6(RGP_i^{t-2}) + f_7(RPI_i^t) + \beta_1(\text{Black proportion}) + \quad (1) \\
 &\quad \beta_2(SVI) + \beta_3(\text{Adults at high risk}) + \beta_4(\text{Medicaid spending})
 \end{aligned}$$

213

214 Where  $\alpha$  represents the intercept,  $\beta_i$  represent the parametric coefficients of each static variable,  
 215 and  $f_i$  are spline smooth functions of the relative dynamic variables. Additionally, a model is  
 216 constructed for the Omicron wave, incorporating an interaction between completed primary  
 217 series and booster rate (Omicron-Booster-RCHR). The Omicron-Booster-RCHR has the form:

218

$$\begin{aligned}
 RCHR_i^t &\sim \text{Gamma}(\mu, \phi) \\
 \log(\mu) &= \alpha + f_1(RCPSR_i^{t-2}, RBR_i^{t-2}) + f_2(RWTR_i^{t-2}) + f_3(RGV_i^{t-2}) + f_4(RPV_i^{t-2}) \\
 &+ f_5(RUV_i^{t-2}) + f_6(RGP_i^{t-2}) + f_7(RPI_i^t) + \beta_1(\text{Black proportion}) + \quad (2) \\
 &\quad \beta_2(SVI) + \beta_3(\text{Adults at high risk}) + \beta_4(\text{Medicaid spending})
 \end{aligned}$$

219

220 Where  $f_1$  represent a smooth interaction function between  $RCPSR_i^{t-2}$  and  $RBR_i^{t-2}$ . For all the  
 221 mentioned models above, the weekly state-level RCHR is assumed to follow a Gamma  
 222 distribution with a log link. This choice of the Gamma family accounts for the positively skewed  
 223 distribution of the outcome variable. We use thin plate regression splines as the smoothing basis  
 224 for all  $f_i$  and set the basis dimension to three to maximize the interpretability of the models. The  
 225 basis dimension refers to the maximum possible complexity of each smooth term; a large basis  
 226 dimension could overfit the data and result in highly non-linear relationships between input and  
 227 outcome variables.

228 To consider the sequential process of infection leading to hospitalization we introduce a time lag  
 229 between each of the input variables relative to the outcome variable, which is denoted by the  
 230 superscript. The timeline of this model is introduced as follows: the modeled relative case-  
 231 hospitalizations rate ( $RCHR_i^t$ ), occur at time  $t$ . Infections resulting in hospitalization, are  
 232 assumed to occur at time  $t-2$ , to account for a one week incubation period [31], and one  
 233 additional week between symptoms onset and hospitalization [32]. Note, this timeline aligns with  
 234 the definition of the CHR variable, which is normalized by the number of reported infections one  
 235 week prior, which assumes a one week delay between when infection occurred and when it is  
 236 reported. To accurately reflect the conditions presented at the time of infection, each of the  
 237 variables related to vaccination ( $RCPSR_i^{t-2}$ ), activity-related engagememnt levels ( $RGV_i^{t-2}$ ,  
 238  $RPV_i^{t-2}$ ,  $RUV_i^{t-2}$ ), policy ( $RGP_i^{t-2}$ ), and testing ( $RWTR_i^{t-2}$ ) are also lagged by two weeks  
 239 relative to the case-hospitalization risk. Lastly, the past infections variable, defined as stated  
 240 above to capture the role of recently acquired immunity from infection in protecting from severe  
 241 disease upon reinfection, is equal to the total infection rate in the population summed over the  
 242 prior 4 to 16 weeks. This time window is explicit in the definition of  $RPI_i^t$  (see Appendix section  
 243 1.2).

244 A secondary set of analogous models treats RCIR as the response variable, namely the Pre-  
 245 Delta-RCIR, the Delta-RCIR, the Omicron-RCIR, and the Omicron-Booster-RCIR. The first




246 three models adopt the same form as equation (1), while the Omicron-Booster-RCIR follows the  
 247 same form as equation (2). To account for the sequential process leading to infections, all lags  
 248 between dynamic covariates, and RCIR have been reduced by one week. This results in eight  
 249 models, with four models fit to RCHR, and four models fit to RCIR. The exact formulation of  
 250 models with RCIR as outcome variable are documented in Appendix section 2.6.

251 The selection of covariates for each model relies on correlation-based feature selection, taking  
 252 into account both Pearson's correlation between variables and the concavity measures derived  
 253 from GAMs. Details regarding feature selection can be found in Appendix sections 2.1 and 2.2.  
 254 The impact of each dynamic variable is quantified by computing the Accumulated Local effects  
 255 (ALE) of each smooth term on outcome variables. The local effect refers to the change in model  
 256 output when a particular input feature is changed while keeping all other features constant. The  
 257 ALE method aggregates the local effects of each input feature across its entire range. By  
 258 accumulating these local effects, we gain insight into how changes in each input variable  
 259 influence the outcome variable across its entire range. Data processing, visualization, and  
 260 analysis were carried out using R 4.0 and Python 3.8.  
 261

### 262 3. Results

#### 263 3.1 GAMs analysis for the relative case-hospitalization rate (RCHR) as the outcome




265 Figure 1: Results for the Pre-Delta-RCHR (Blue), the Delta-RCHR (Orange), and the Omicron-  
266 RCHR (Red). a-g: Accumulated local effects (ALE) of dynamic variables. Shaded areas in each  
267 plot indicate 95% confidence intervals. h-k: Estimated slopes for each static variables, the upper  
268 and lower band indicate 95% confidence intervals. l: Deviance explained for each model. ‘\*\*\*\*’:  
269 variable significant at  $p < 0.001$ . ‘\*\*\*’: variable significant at  $p < 0.01$ . ‘\*’: variable significant at  
270  $p < 0.05$ . ‘’: variable significant at  $p > 0.05$ .

271 In our analysis, we evaluated goodness-of-fit based on several metrics. For models with relative  
272 case-hospitalization risk (RCHR) as the outcome variable, the deviance explained ranges  
273 between 46.8% and 72.3% (Figure 1l) for each variant wave. Moreover, we assessed the  
274 correlation between observed RCHR and predicted RCHR, which exhibited strong positive  
275 correlations ranging from 0.67 to 0.81 (Appendix section 3.1). These findings provide  
276 compelling evidence of the models' effectiveness in capturing and predicting the case-  
277 hospitalization rate.

278 The relative completed primary series rate, and relative previous infections consistently  
279 displayed strong negative associations with RCHR across different waves (Figures 1a and 1b).  
280 Of particular note is that relative previous infections consistently ranked the highest in terms of  
281 ALE across the different waves. Figure 1c reveals the impact of the relative government  
282 response index gradually flattening out from the pre-Delta to the Omicron wave. Regarding  
283 activity-related engagement levels, their effects on RCHR appear inconsistent across different  
284 waves, as exemplified by the relative physician visits, which slightly changed from negative to  
285 positive effects as the analysis progressed from the pre-Delta to the Omicron wave (Figure 1e).  
286 Lastly, the relative weekly testing rate served as a control variable to address the state-level  
287 differences in testing rates. The result revealed a negative correlation between the relative  
288 weekly testing rate and RCHR. Nevertheless, it is noteworthy that this association exhibited a  
289 decrease from the pre-Delta wave to the Omicron wave, as illustrated in Figure 1g.

290 Regarding the static variables, adults at high risk exhibited a declining positive association with  
291 RCHR. Additionally, states with higher Social Vulnerability Index (SVI) consistently showed  
292 higher RCHR. Among racial groups, the proportion of Black positively associated with RCHR  
293 during the Pre-Delta wave but did not exhibit a significant impact since the Delta wave. With  
294 healthcare systems variables, Medicaid spending per person consistently showed a negative  
295 association with RCHR.


296



297  
 298 Figure 2: Results of Omicron-Booster-RCHR for just the Omicron wave with the additional  
 299 inclusion of an interaction effect between the relative completed primary series rate and the  
 300 relative booster rate. a: Two-dimensional contour plot for the interaction between relative  
 301 completed primary series rate and relative booster rate. The deeper red indicates a more positive  
 302 effect on the RCHR, and the deeper blue indicates a more negative effect to the RCHR. b-g:  
 303 Accumulated local effects (ALE) of dynamic variables. Shaded areas in each plot indicate 95%  
 304 confidence intervals. h: Estimated slopes for each static variables, the upper and lower band  
 305 indicate 95% confidence intervals. ‘\*\*\*’: variable significant at  $p < 0.001$ . ‘\*\*’: variable  
 306 significant at  $p < 0.01$ . ‘\*’: variable significant at  $p < 0.05$ . ‘’: variable significant at  $p > 0.05$ .

307 With the exception of the completed primary series rate, the effects of all other variables  
 308 modeled in the Omicron-Booster-RCHR remained consistent with the results for the Omicron-  
 309 RCHR shown in Figure 1. Figures 2a show the interaction between two vaccine-related variables  
 310 in a two-dimensional variable space. The solid black lines represent the contour lines. The  
 311 contour lines correspond to points that have an equivalent impact on the hospitalization rate,  
 312 with the values marked on each line indicating the actual interaction effect of these points on the  
 313 RCHR. Figure 2a reveals that the RCHR decreases along the direction of increasing the relative  
 314 booster rate and the relative completed primary series rate.

315  
 316 3.2 GAMs analysis for the relative reported case-incidence rate (RCIR) as the outcome



317

318 Figure 3: Results for the Pre-Delta-RCIR (Blue), the Delta-RCIR (Orange), and the Omicron-  
 319 RCIR (Red). a-g: Accumulated local effects (ALE) of dynamic variables. Shaded areas in each  
 320 plot indicate 95% confidence intervals. h-k: Estimated slopes for each static variables, the upper  
 321 and lower band indicate 95% confidence intervals. l: Deviance explained for each model. ‘\*\*\*’:  
 322 variable significant at  $p < 0.001$ . ‘\*\*’: variable significant at  $p < 0.01$ . ‘\*’: variable significant at  
 323  $p < 0.05$ . ‘’: variable significant at  $p > 0.05$ .


324 The GAMs using relative reported case-incidence rate (RCIR) as the outcome variable  
 325 consistently demonstrate lower performance than those GAMs with RCHR as the outcome  
 326 variable. Specifically, all GAMs for RCIR have deviance explained values below 40%, and  
 327 correlations between observed RCIR and predicted RCIR range from 0.43 to 0.61 (Appendix  
 328 section 3.2). The observed performance pattern indicates a more intricate and dynamic  
 329 relationship concerning COVID-19 transmission, particularly evident during the Omicron wave.

330 Figure 3a illustrates a strong negative association between the relative completed primary series  
 331 rate and RCIR during the Pre-Delta and Delta waves. However, this association vanished during  
 332 the Omicron wave, coinciding with a decline in model performance (Figure 3l). The ALE plot of  
 333 the relative previous infection rate (Figure 2b) revealed an insignificant association between  
 334 previous infection and RCIR during the pre-Delta and Delta waves but a significant negative  
 335 association during the Omicron wave. Additionally, when the relative government policy index  
 336 is greater than one, the ALE plots demonstrate a negative trend; however, the magnitude of this

337 effect is relatively smaller compared to other dynamic variables examined in the analysis.  
 338 Similar to GAMs for RCHR, the activity-related engagement levels exhibited inconsistent  
 339 patterns across different waves. Notably, the ALE of relative university visits reverses direction  
 340 from negative to positive between the pre-Delta wave and the later two waves.

341 For the static variables, adults at high risk were consistently positively associated with RCIR  
 342 across different waves. However, the other static variables, including racial groups, SVI, and  
 343 healthcare expenditures, do not show a consistent or significant impact across different waves.

344 Figure 4 illustrates the results of the Omicron-Booster-RCIR for just the Omicron wave with the  
 345 additional inclusion of an interaction effect between the completed primary series rate and the  
 346 relative booster rate. This interaction effect is presented as a dimension contour map in figure 4a.



347  
 348 Figure 4: Results of the Omicron-Booster-RCIR for just the Omicron wave with the additional  
 349 inclusion of an interaction effect between the relative completed primary series rate and the  
 350 relative booster rate. a: Two-dimensional contour plot for the interaction between relative  
 351 completed primary series rate and relative booster rate. b-g: Accumulated local effects (ALE) of  
 352 dynamic variables. Shaded areas in each plot indicate 95% confidence intervals. h: Estimated  
 353 slopes for each static variables, the upper and lower band indicate 95% confidence intervals.  
 354 ‘\*\*\*’: variable significant at  $p < 0.001$ . ‘\*\*’: variable significant at  $p < 0.01$ . ‘\*’: variable  
 355 significant at  $p < 0.05$ . ‘’: variable significant at  $p > 0.05$ .



356 The incorporation of the relative booster rate does not result in an improvement in the model fit;  
357 the deviance explained for Model Omicron-Booster-RCIR remains at 17%. As depicted in Figure  
358 4a, it is evident that only states with both a high relative completed primary series rate and a high  
359 relative booster rate exhibits a slightly negative impact, approximately -0.1, on the RCIR. The  
360 findings from Model Omicron-RCIR, when combined with Omicron-Booster-RCIR, suggest that  
361 the covariates examined in this study do not contribute significantly to explaining the variation in  
362 RCIR during the Omicron wave. These results highlight the need for further research to identify  
363 other factors that may better capture the dynamics of COVID-19 transmission during this  
364 specific period.

365

#### 366 **4. Discussion**

367 This analysis aims to characterize the relationship between population-level COVID-19 vaccine  
368 administration and pandemic-induced healthcare burdens, taking into account essential and  
369 confounding real-world processes. Our results point to three significant conclusions:

- 370 • Population-level vaccination is always significantly associated with reduced COVID-19  
371 case-hospitalization risk.
- 372 • Increased recent (1-4 months prior) infections are also consistently and strongly  
373 associated with reduced case-hospitalization risk.
- 374 • Local factors, activity-related engagement levels, and policy measures are important to  
375 the model's explanatory power, supporting the importance of considering these factors on  
376 population-level outcomes. However, their associations are inconsistent over time and  
377 across different variants.

378 Each of these conclusions is explained in more detail in the sections below. In each section, we  
379 discuss the findings regarding case-hospitalization risk and compare them with the results related  
380 to the reported case incidence rate. In general, our results strongly support the importance of  
381 population-level vaccination and align with extant research on the role of acquired immunity in  
382 reducing severe outcomes. However, it should be noted that the case incidence rate has a reduced  
383 association with vaccination during the Omicron wave and much less consistently meaningful  
384 associations with previous infection rates. Additionally, our analysis reflects the complexity of  
385 the evolution of human behavior during the pandemic, given the dynamic role of activity-related  
386 engagement levels and policy. It also supports the recognition of the epidemiological  
387 vulnerability of socially and economically underserved communities.

#### 388 ***4.1 Vaccines protect against COVID-19 case-hospitalization risk for pre-Delta, Delta and*** 389 ***Omicron waves***

390 Our study reveals a strong and statistically significant association between vaccine uptake rates  
391 and reduced COVID-19 case-hospitalization risk. This relationship was consistent across each of  
392 the variant waves modeled, and is consistent with earlier findings that vaccine protection against  
393 severe illnesses does not significantly wane in response to new variants. In contrast, when we  
394 modeled reported case-incidence rates as the response variable, we observed a decreasing effect  
395 of vaccines from the pre-Delta to the Omicron wave (Figure 3a). This outcome aligns with



396 existing literature highlighting the rapid waning of the vaccines' effectiveness against infection  
397 [33,34]. Nonetheless, while vaccines may offer reduced protection against infection, our results  
398 indicate that they continue to provide substantial protection against hospitalization risk and help  
399 alleviate the burden on healthcare systems. Additionally, although the value of booster shots for  
400 protection against severe cases of COVID-19 is still being studied [35], results from our analysis  
401 provide evidence supporting the effectiveness of booster doses against hospitalization risk  
402 caused by the Omicron variant (Figure 2). Conversely, the findings obtained from our Omicron-  
403 Booster-RCIR model reveal that the interaction between the booster and completed primary  
404 series rates has a relatively limited impact on Omicron infection (Figure 4). However, it is  
405 crucial to emphasize that despite the diminished effectiveness of mRNA boosters against  
406 Omicron infections, vaccines still serve the essential purpose of reducing the harm of COVID-19  
407 in the face of emerging variants.

#### 408 ***4.2 Immunity from recent infection protects against COVID-19 case-hospitalization risk upon*** 409 ***reinfection***

410 Higher past COVID-19 infection levels in a population are associated with a decrease in  
411 COVID-19 case-hospitalization risk, indicating immunity gained from infection can provide  
412 some protection against severe disease in the event of reinfection in the future, but only for a  
413 limited period of time. Our study utilized the total number of cases reported in a 12-week  
414 window, ranging from 4 to 16 weeks prior to the time period modeled, as a proxy for recently  
415 acquired immunity, and found a strong negative association between the previous infection rate  
416 and future case-hospitalization risk. These results were consistent across the different variant  
417 waves. This finding aligns with other case-control studies that found previous infections showed  
418 strong effectiveness against severe, critical, or fatal COVID-19 [6,36]. Our analysis indicates that  
419 prior infections from up to 6 months ahead are associated with decreased hospitalization risk, but  
420 4 to 16 weeks has the strongest effect (see Appendix sections 2.4 and 2.5 for this sensitivity  
421 analysis). While the waning of natural immunity has been established in molecular and clinical  
422 research [37], our analysis provides additional insight at the population-level. In our models with  
423 case-incidence rate as the outcome variable, we found an insignificant association between  
424 previous infection and case-incidence rate during the pre-Delta and Delta waves. However,  
425 during the Omicron wave, there was a significant negative association (Figure 3b). This finding  
426 contrasts with existing literature that found, at the individual level, previous infection protected  
427 against infection pre-Omicron, but this effectiveness decreases substantially during the Omicron  
428 wave [38]. Nevertheless, at the population level, the number of infected individuals is  
429 considerably higher during the Omicron wave than earlier, while a smaller proportion remains  
430 susceptible. Consequently, the cumulative impact of previous infections becomes more  
431 pronounced. These results highlight that previous infections have a variable and inconsistent  
432 impact on reinfection at the individual and population levels.

#### 433 ***4.3 Local factors contribute to variation in COVID-19 health outcomes***

434 Existing clinical and statistical studies [14,16,17] have identified critical indicators for COVID-  
435 19 health outcomes including demographics, comorbidities, social vulnerability index (SVI), and  
436 healthcare expenditures. Results from our model using RCHR as outcome variables indicate that

437 the SVI is positively associated with COVID-19 case-hospitalization risk across all variant  
438 waves (Figure 1i). This finding is consistent with existing literature [14,17], which suggests that  
439 individuals from socially vulnerable regions are more likely to experience harmful COVID-19  
440 outcomes. For each new variant wave, the proportion of adults at high risk was less associated  
441 with case-hospitalization risk than for the prior wave (Figure 1h). This result aligns with a cohort  
442 study that the hazard ratio of hospital admissions with the Omicron variant, compared to the  
443 Delta variant, showed a more significant drop in the elder age group compared to individuals  
444 younger than 20 [39]. Our results reveal an insignificant association between black proportion  
445 and case-hospitalization risk during the Delta and Omicron waves, which differs from previously  
446 identified positive associations across all waves [14]. In the United States, the eligibility for  
447 Medicaid varies by state, but generally, individuals and families with incomes up to 138% of the  
448 federal poverty level may qualify for coverage [40]. Our results reveal a consistent negative  
449 association between state-level Medicaid spending per person and COVID-19 case-  
450 hospitalization risk (Figure 1k), which indicates the potential protective effect of healthcare  
451 expenditures in mitigating the impact of the pandemic on vulnerable groups. In contrast to the  
452 case-hospitalization risk models, the case-incidence rate models indicate that there is no evidence  
453 for consistent or significant associations with demographics, SVI, or healthcare expenditures  
454 across variant waves, except for adults at high risk consistently positively associated with case-  
455 incidence rate (Figure 3). These results suggest that dynamic COVID-19 infection risk is  
456 complex and changes over time, and the factors contributing to transmission vary across waves.  
457 Further research is needed for a more comprehensive understanding of the complex and evolving  
458 nature of COVID-19 transmission.

#### 459 ***4.4 Activity-related engagement levels are associated with COVID-19 health outcomes***

460 At the beginning of the pandemic, several studies evaluated the association between mobility and  
461 COVID-19 transmission with inconsistent findings [41,42]. One possible reason for this  
462 inconsistency is that aggregated mobility data may not accurately reflect the risk of dynamically  
463 changing human behaviors, given that a minority of travel activities could be accountable for a  
464 significant majority of infections [43]. Furthermore, the connection between mobility and  
465 harmful health outcomes remains unclear. Our study uses disaggregated mobility patterns to  
466 capture diverse behaviors between populations, specifically relative activity-related engagement  
467 levels, to explore the association between these variables and COVID-19 severity. To achieve  
468 this, we divided activities into subcategories based on their purpose. University visits were used  
469 to represent school-related activities, gym visits to signify high-risk indoor activities, and  
470 physician visits to indicate healthcare-related visits.

471 Results shown in Figure 1d indicate that the state-week pairs with relatively higher gym visits  
472 are expected to observe higher case-hospitalization risk during the Pre-Delta wave. However,  
473 this association did not reach statistical significance during the Delta and Omicron waves. In  
474 contrast, when we modeled the case-incidence rate as the outcome variable, our analysis revealed  
475 a minor effect of gym visits, as shown in Figure 3d. The positive impact of gym visits during the  
476 Pre-Delta wave may be linked to infections among unvaccinated individuals engaging in indoor  
477 activities. It is supported by existing research that unvaccinated individuals have a 2.6 times

478 higher likelihood of contracting SARS-CoV-2 than vaccinated individuals during indoor  
479 activities [44]. Moreover, unvaccinated individuals exhibit a higher likelihood of hospitalization  
480 [45], leading to a strong positive association between gym visits and case-hospitalization risk  
481 during the initial phases of vaccination distribution. In addition to indoor activity, we also  
482 observed a significant association between case-hospitalization risk and overall visits to hospitals,  
483 medical centers, and Outpatient Care Centers. Unlike indoor activity, this association  
484 transitioned from negative to positive between the pre-Delta to Omicron wave. One possible  
485 explanation for this finding is that as the pandemic evolved, the public became more familiar  
486 with the disease and more tolerant of at-home symptom management; thus, those COVID-19  
487 patients that sought medical care were more likely to be those with more severe symptoms.  
488 Finally, visits to the university were found to have a relatively minor impact on case-  
489 hospitalization risk. We hypothesize that this is due to the young and relatively healthy  
490 demographic that frequents visiting schools, while still vulnerable to contracting the SARS-CoV-  
491 2 virus, they are less likely to experience severe outcomes from COVID-19 infection. This  
492 hypothesis is further supported by the findings from the case-incidence rate model, which  
493 identified a positive association with university visits during the Delta and Omicron waves  
494 (Figure 3d). It is worth noting that during the Pre-Delta wave, school visits negatively impacted  
495 the case-hospitalization risk. However, this impact changed to a positive association for the later  
496 waves. These observations align with existing research, which has demonstrated that the younger  
497 population exhibits the highest increase in susceptibility to the Delta variant compared to the pre-  
498 Delta variant [46].

#### 499 ***4.5 More stringent government public health policy is associated with reduced COVID-19*** 500 ***case-hospitalization risk***

501 Our results indicate that more stringent government policies were associated with reduced  
502 COVID-19 case-hospitalization risk during the Pre-Delta and Delta wave. This is consistent with  
503 previous studies [47]. In particular, we found that state-week pairs with a significantly high  
504 government response index (indicating stricter policy) have a stronger negative effect on the  
505 case-hospitalization risk (Figure 1c). However, this negative effect decreased over time, and was  
506 least evident during the Omicron wave. The reduced effect of the policy during Omicron is likely  
507 due to a complex combination of factors, including the increasing population level immunity  
508 from both widespread adoptions of vaccines and prior exposure providing more protection from  
509 severe disease during this period, combined with a reduction in the government's response to the  
510 pandemic over time.

511 Additionally, weekly testing rates were shown to be negatively associated with case-  
512 hospitalization risk. While this result does not imply a causative relationship between testing rate  
513 and COVID-19 severity, there are various reasons why testing rates may be linked to case-  
514 hospitalization risk. Firstly, it represents a proxy input feature to capture the level of healthcare  
515 infrastructure available to a population. Second, it directly impacts the reported case incidence  
516 rate, as the number of reported cases in a region is a direct function of local testing availability,  
517 thus increased testing will lead to higher reported case rates, and lower case-hospitalization risk.  
518 Third, increased testing can lead to more cases being identified, and thus impact people's

519 awareness and behavior during an outbreak. For these reasons testing rate is included as a  
520 potential control factor in our model.

521

#### 522 **4.6 Limitations**

523 As with all modeling studies, this work is subject to several limitations. Firstly, this study was  
524 primarily designed to determine the association between various potential risk factors and  
525 COVID-19 outcomes, rather than to establish causality between these variables. Thus, our  
526 findings may reflect the role of unobserved confounding factors excluded from our study.  
527 Another potential limitation is due to the application at the state-level. The aggregation of the  
528 data to the state-level is unable to capture the heterogeneities of the communities within each  
529 state, and it is possible that different associations exist at the local level, than are identified at the  
530 state-level. Additionally, while we believe the use of the case-hospitalization risk in a given state  
531 at a given time is a plausible choice as a proxy for disease severity at an individual-level, and  
532 captures the burden on the healthcare system at a population-level. However, it is subject to  
533 variable case reporting and data quality across states, which may arise due to uneven testing  
534 capacity, reporting delays or at-home testing. Lastly, it is important to acknowledge that our  
535 variable transformation, while facilitating a deeper understanding of relative changes, does come  
536 with the inherent consequence of diminishing the original meaning these variables initially  
537 conveyed.

#### 538 **5. Conclusions**

539 This research utilizes publicly available real-world data to provide robust evidence of the  
540 efficacy of vaccines against COVID-19 case-hospitalization risk across various variant waves in  
541 the United States. More importantly, this paper concludes that booster shots offer additional  
542 protection against severe COVID-19 during the Omicron waves. Despite the emergence of new  
543 variants, vaccines remain the most effective intervention for mitigating the harm of COVID-19  
544 and reducing burden on healthcare systems. Therefore, given the ongoing threat posed by  
545 COVID-19 and its potential variants, vaccines continue to be the best line of defense for  
546 protecting public health and preventing the further spread of the virus.

547

#### 548 **Availability of data and materials**

549 All the data and code used for the analysis is available from  
550 [https://github.com/hongru94/vaccination\\_rate\\_GAMs](https://github.com/hongru94/vaccination_rate_GAMs).

#### 551 **Competing interests**

552 The authors declare no potential conflicts of interest.

#### 553 **Funding**

554 This work was funded the NSF RAPID Award ID 2108526, NSF Award ID 2229996, and  
555 CDC Contract #75D30120C09570.

#### 556 **Author's Contributions**

557 LG, and HD contributed to the conceptualization and design of the study. HD and SS collected  
558 the data and conducted the analysis. HD led the writing of the original draft. HD, SS, and LG  
559 edited the manuscript, discussed the results, and provided feedback regarding the manuscript. LG  
560 supervised the study and acquired funding. HD and SS have verified the underlying data. All  
561 authors had full access to the data and approved the manuscript for publication.

## 562 **Acknowledgments**

563 We want to thank Maximilian Marshall for providing valuable insights and suggestions that have  
564 contributed to enhancing the quality of this paper.

565

## 566 **Reference**

- 567 [1]Baden LR, El Sahly HM, Essink B, Kotloff K, Frey S, Novak R, et al. Efficacy and Safety of the  
568 mRNA-1273 SARS-CoV-2 Vaccine. *N Engl J Med* 2021;384:403–16.  
569 <https://doi.org/10.1056/NEJMoa2035389>.
- 570 [2]Sadoff J, Gray G, Vandebosch A, Cárdenas V, Shukarev G, Grinsztejn B, et al. Safety and Efficacy of  
571 Single-Dose Ad26.COV2.S Vaccine against Covid-19. *N Engl J Med* 2021;384:2187–201.  
572 <https://doi.org/10.1056/NEJMoa2101544>.
- 573 [3]Thomas SJ, Moreira ED, Kitchin N, Absalon J, Gurtman A, Lockhart S, et al. Safety and Efficacy of  
574 the BNT162b2 mRNA Covid-19 Vaccine through 6 Months. *N Engl J Med* 2021;385:1761–73.  
575 <https://doi.org/10.1056/NEJMoa2110345>.
- 576 [4]Kim JH, Marks F, Clemens JD. Looking beyond COVID-19 vaccine phase 3 trials. *Nat Med*  
577 2021;27:205–11. <https://doi.org/10.1038/s41591-021-01230-y>.
- 578 [5]Patel MK, Bergeri I, Bresee JS, Cowling BJ, Crowcroft NS, Fahmy K, et al. Evaluation of post-  
579 introduction COVID-19 vaccine effectiveness: Summary of interim guidance of the World Health  
580 Organization. *Vaccine* 2021;39:4013–24. <https://doi.org/10.1016/j.vaccine.2021.05.099>.
- 581 [6]Altarawneh HN, Chemaitelly H, Ayoub HH, Tang P, Hasan MR, Yassine HM, et al. Effects of  
582 Previous Infection and Vaccination on Symptomatic Omicron Infections. *N Engl J Med*  
583 2022;387:21–34. <https://doi.org/10.1056/NEJMoa2203965>.
- 584 [7]Haas EJ, Angulo FJ, McLaughlin JM, Anis E, Singer SR, Khan F, et al. Impact and effectiveness of  
585 mRNA BNT162b2 vaccine against SARS-CoV-2 infections and COVID-19 cases, hospitalisations,  
586 and deaths following a nationwide vaccination campaign in Israel: an observational study using  
587 national surveillance data. *The Lancet* 2021;397:1819–29. [https://doi.org/10.1016/S0140-6736\(21\)00947-8](https://doi.org/10.1016/S0140-6736(21)00947-8).
- 588 [8]Gram MA, Emborg H-D, Schelde AB, Friis NU, Nielsen KF, Moustsen-Helms IR, et al. Vaccine  
589 effectiveness against SARS-CoV-2 infection or COVID-19 hospitalization with the Alpha, Delta, or  
590 Omicron SARS-CoV-2 variant: A nationwide Danish cohort study. *PLOS Med* 2022;19:e1003992.  
591 <https://doi.org/10.1371/journal.pmed.1003992>.
- 592 [9]Ng OT, Marimuthu K, Lim N, Lim ZQ, Thevasagayam NM, Koh V, et al. Analysis of COVID-19  
593 Incidence and Severity Among Adults Vaccinated With 2-Dose mRNA COVID-19 or Inactivated  
594 SARS-CoV-2 Vaccines With and Without Boosters in Singapore. *JAMA Netw Open*  
595 2022;5:e2228900. <https://doi.org/10.1001/jamanetworkopen.2022.28900>.
- 596 [10] Agrawal U, Bedston S, McCowan C, Oke J, Patterson L, Robertson C, et al. Severe COVID-19  
597 outcomes after full vaccination of primary schedule and initial boosters: pooled analysis of national  
598 prospective cohort studies of 30 million individuals in England, Northern Ireland, Scotland, and  
599 Wales. *The Lancet* 2022;400:1305–20. [https://doi.org/10.1016/S0140-6736\(22\)01656-7](https://doi.org/10.1016/S0140-6736(22)01656-7).
- 600 [11] Watson OJ, Barnsley G, Toor J, Hogan AB, Winskill P, Ghani AC. Global impact of the first year  
601 of COVID-19 vaccination: a mathematical modelling study. *Lancet Infect Dis* 2022;22:1293–302.  
602 [https://doi.org/10.1016/S1473-3099\(22\)00320-6](https://doi.org/10.1016/S1473-3099(22)00320-6).
- 603



- 604 [12] Wang R, Wang J, Hu T, Zhou X-H. Population-Level Effectiveness of COVID-19 Vaccination  
605 Program in the United States: Causal Analysis Based on Structural Nested Mean Model. *Vaccines*  
606 2022;10:726. <https://doi.org/10.3390/vaccines10050726>.
- 607 [13] Shioda K. Population-Level Relative Effectiveness of the COVID-19 Vaccines and the Contribution  
608 of Naturally Acquired Immunity n.d.
- 609 [14] Bollyky TJ, Castro E, Aravkin AY, Bhangdia K, Dalos J, Hulland EN, et al. Assessing COVID-19  
610 pandemic policies and behaviours and their economic and educational trade-offs across US states  
611 from Jan 1, 2020, to July 31, 2022: an observational analysis. *The Lancet*  
612 2023;S0140673623004610. [https://doi.org/10.1016/S0140-6736\(23\)00461-0](https://doi.org/10.1016/S0140-6736(23)00461-0).
- 613 [15] Hu S, Xiong C, Zhao Y, Yuan X, Wang X. Vaccination, human mobility, and COVID-19 health  
614 outcomes: Empirical comparison before and during the outbreak of SARS-CoV-2 B.1.1.529  
615 (Omicron) variant. *Vaccine* 2023;S0264410X23006175.  
616 <https://doi.org/10.1016/j.vaccine.2023.05.056>.
- 617 [16] Ogedegbe G, Ravenell J, Adhikari S, Butler M, Cook T, Francois F, et al. Assessment of  
618 racial/ethnic disparities in hospitalization and mortality in patients with COVID-19 in New York  
619 City. *JAMA Netw Open* 2020;3:e2026881–e2026881.
- 620 [17] Gallo Marin B, Aghagoli G, Lavine K, Yang L, Siff EJ, Chiang SS, et al. Predictors of COVID-19  
621 severity: a literature review. *Rev Med Virol* 2021;31:1–10.
- 622 [18] Dong E, Du H, Gardner L. An interactive web-based dashboard to track COVID-19 in real time.  
623 *Lancet Infect Dis* 2020;20:533–4.
- 624 [19] HHS Protect Public Data Hub n.d. <https://public-data-hub-dhhs.hub.arcgis.com/> (accessed January  
625 13, 2023).
- 626 [20] COVID-19/data\_tables/vaccine\_data/us\_data at master · govex/COVID-19. GitHub n.d.  
627 <https://github.com/govex/COVID-19> (accessed January 13, 2023).
- 628 [21] CDC. COVID Data Tracker. Cent Dis Control Prev 2020. <https://covid.cdc.gov/covid-data-tracker>  
629 (accessed January 13, 2023).
- 630 [22] COVID-19/data\_tables/testing\_data at master · govex/COVID-19. GitHub n.d.  
631 <https://github.com/govex/COVID-19> (accessed January 13, 2023).
- 632 [23] Places Data Curated for Accurate Geospatial Analytics | SafeGraph n.d. <https://www.safegraph.com>  
633 (accessed January 13, 2023).
- 634 [24] Du H, Dong E, Badr HS, Petrone ME, Grubaugh ND, Gardner LM. Incorporating variant  
635 frequencies data into short-term forecasting for COVID-19 cases and deaths in the USA: a deep  
636 learning approach. *EBioMedicine* 2023;89:104482. <https://doi.org/10.1016/j.ebiom.2023.104482>.
- 637 [25] Hale T, Webster S, Petherick A, Phillips T, Kira B. Oxford COVID-19 government response tracker  
638 (OxCGRT). Last Update 2020;8:30.
- 639 [26] Bureau UC. State Population by Characteristics: 2010-2019. CensusGov n.d.  
640 <https://www.census.gov/data/datasets/time-series/demo/popest/2010s-state-detail.html> (accessed  
641 April 30, 2023).
- 642 [27] CDC/ATSDR SVI Data and Documentation Download | Place and Health | ATSDR 2022.  
643 [https://www.atsdr.cdc.gov/placeandhealth/svi/data\\_documentation\\_download.html](https://www.atsdr.cdc.gov/placeandhealth/svi/data_documentation_download.html) (accessed  
644 February 13, 2023).
- 645 [28] Adults at Higher Risk of Serious Illness if Infected with Coronavirus. KFF 2020.  
646 [https://www.kff.org/other/state-indicator/adults-at-higher-risk-of-serious-illness-if-infected-with-](https://www.kff.org/other/state-indicator/adults-at-higher-risk-of-serious-illness-if-infected-with-coronavirus/)  
647 [coronavirus/](https://www.kff.org/other/state-indicator/adults-at-higher-risk-of-serious-illness-if-infected-with-coronavirus/) (accessed February 13, 2023).
- 648 [29] Health Insurance Coverage of the Total Population. KFF 2022. [https://www.kff.org/other/state-](https://www.kff.org/other/state-indicator/total-population/)  
649 [indicator/total-population/](https://www.kff.org/other/state-indicator/total-population/) (accessed April 30, 2023).
- 650 [30] Khare S, Gurry C, Freitas L, Schultz MB, Bach G, Diallo A, et al. GISAID's role in pandemic  
651 response. *China CDC Wkly* 2021;3:1049.
- 652 [31] Quesada JA, López-Pineda A, Gil-Guillén VF, Arriero-Marín JM, Gutiérrez F, Carratala-Munuera  
653 C. Incubation period of COVID-19: A systematic review and meta-analysis. *Rev Clínica Esp Engl*  
654 *Ed* 2021;221:109–17. <https://doi.org/10.1016/j.rceng.2020.08.002>.



- 655 [32] Faes C, Abrams S, Van Beckhoven D, Meyfroidt G, Vlieghe E, Hens N, et al. Time between  
656 symptom onset, hospitalisation and recovery or death: statistical analysis of Belgian COVID-19  
657 patients. *Int J Environ Res Public Health* 2020;17:7560.
- 658 [33] Goldberg Y, Mandel M, Bar-On YM, Bodenheimer O, Freedman L, Haas EJ, et al. Waning  
659 Immunity after the BNT162b2 Vaccine in Israel. *N Engl J Med* 2021;385:e85.  
660 <https://doi.org/10.1056/NEJMoa2114228>.
- 661 [34] Tenforde MW, Self WH, Naioti EA, Ginde AA, Douin DJ, Olson SM, et al. Sustained effectiveness  
662 of Pfizer-BioNTech and Moderna vaccines against COVID-19 associated hospitalizations among  
663 adults—United States, March–July 2021. *Morb Mortal Wkly Rep* 2021;70:1156.
- 664 [35] Chenchula S, Karunakaran P, Sharma S, Chavan M. Current evidence on efficacy of COVID-19  
665 booster dose vaccination against the Omicron variant: A systematic review. *J Med Virol*  
666 2022;94:2969–76.
- 667 [36] Carazo S, Skowronski DM, Brisson M, Barkati S, Sauvageau C, Brousseau N, et al. Protection  
668 against omicron (B. 1.1. 529) BA. 2 reinfection conferred by primary omicron BA. 1 or pre-omicron  
669 SARS-CoV-2 infection among health-care workers with and without mRNA vaccination: a test-  
670 negative case-control study. *Lancet Infect Dis* 2023;23:45–55.
- 671 [37] Bobrovitz N, Ware H, Ma X, Li Z, Hosseini R, Cao C, et al. Protective effectiveness of previous  
672 SARS-CoV-2 infection and hybrid immunity against the omicron variant and severe disease: a  
673 systematic review and meta-regression. *Lancet Infect Dis* 2023;23:556–67.  
674 [https://doi.org/10.1016/S1473-3099\(22\)00801-5](https://doi.org/10.1016/S1473-3099(22)00801-5).
- 675 [38] Altarawneh HN, Chemaitelly H, Hasan MR, Ayoub HH, Qassim S, AlMukdad S, et al. Protection  
676 against the Omicron Variant from Previous SARS-CoV-2 Infection. *N Engl J Med* 2022;386:1288–  
677 90. <https://doi.org/10.1056/NEJMc2200133>.
- 678 [39] Nyberg T, Ferguson NM, Nash SG, Webster HH, Flaxman S, Andrews N, et al. Comparative  
679 analysis of the risks of hospitalisation and death associated with SARS-CoV-2 omicron (B.1.1.529)  
680 and delta (B.1.617.2) variants in England: a cohort study. *The Lancet* 2022;399:1303–12.  
681 [https://doi.org/10.1016/S0140-6736\(22\)00462-7](https://doi.org/10.1016/S0140-6736(22)00462-7).
- 682 [40] Blavin F, Karpman M, Kenney GM, Sommers BD. Medicaid versus marketplace coverage for near-  
683 poor adults: effects on out-of-pocket spending and coverage. *Health Aff (Millwood)* 2018;37:299–  
684 307.
- 685 [41] Badr HS, Du H, Marshall M, Dong E, Squire MM, Gardner LM. Association between mobility  
686 patterns and COVID-19 transmission in the USA: a mathematical modelling study. *Lancet Infect*  
687 *Dis* 2020;20:1247–54.
- 688 [42] Kraemer MU, Yang C-H, Gutierrez B, Wu C-H, Klein B, Pigott DM, et al. The effect of human  
689 mobility and control measures on the COVID-19 epidemic in China. *Science* 2020;368:493–7.
- 690 [43] Chang S, Pierson E, Koh PW, Gerardin J, Redbird B, Grusky D, et al. Mobility network models of  
691 COVID-19 explain inequities and inform reopening. *Nature* 2021;589:82–7.  
692 <https://doi.org/10.1038/s41586-020-2923-3>.
- 693 [44] Wienkes H, Vilen K, Lorentz A, Gerlach D, Wang X, Saupe A, et al. Transmission of and Infection  
694 With COVID-19 Among Vaccinated and Unvaccinated Attendees of an Indoor Wedding Reception  
695 in Minnesota. *JAMA Netw Open* 2022;5:e220536.  
696 <https://doi.org/10.1001/jamanetworkopen.2022.0536>.
- 697 [45] Havers FP, Pham H, Taylor CA, Whitaker M, Patel K, Anglin O, et al. COVID-19-Associated  
698 Hospitalizations Among Vaccinated and Unvaccinated Adults 18 Years or Older in 13 US States,  
699 January 2021 to April 2022. *JAMA Intern Med* 2022;182:1071.  
700 <https://doi.org/10.1001/jamainternmed.2022.4299>.
- 701 [46] Chun JY, Jeong H, Kim Y. Age-Varying Susceptibility to the Delta Variant (B.1.617.2) of SARS-  
702 CoV-2. *SSRN Electron J* 2021. <https://doi.org/10.2139/ssrn.3951778>.
- 703 [47] Hale T, Angrist N, Hale AJ, Kira B, Majumdar S, Petherick A, et al. Government responses and  
704 COVID-19 deaths: Global evidence across multiple pandemic waves. *PLoS One* 2021;16:e0253116.  
705  
706  
707

708  
709  
710  
711  
712  
713  
714  
715  
716  
717  
718  
719  
720  
721  
722  
723  
724  
725  
726  
727

Supplementary Materials for

**Association between vaccination rates and COVID-19 health outcomes in the United States: a population-level statistical analysis**

Hongru Du MS<sup>1,2,\*</sup>, Samee Saiyed MSE<sup>1,2</sup>, and Lauren M. Gardner PhD<sup>1,2,3</sup>

<sup>1</sup>Center for Systems Science and Engineering, Johns Hopkins University, Baltimore, MD 21218, USA.

<sup>2</sup>Department of Civil and Systems Engineering, Johns Hopkins University, Baltimore, MD 21218, USA.

<sup>3</sup>Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, 21205, USA.

\*Corresponding author. Johns Hopkins University, 3400 N. Charles Street, Shaffer 4, Baltimore, MD, 21218, USA.

E-mail address: [hdu9@jhu.edu](mailto:hdu9@jhu.edu) (Hongru Du)

## Table of Contents

|  |           |
|--|-----------|
| <b>1. Supplementary Data</b> .....   | <b>23</b> |
| <b>1.1 Preprocessing of genomic data</b> .....   | <b>23</b> |
| <b>1.2 Variables description</b> .....   | <b>24</b> |
| <b>1.3 Preprocessing of mobility data</b> .....  | <b>28</b> |
| <b>2. Supplementary Methods</b> .....  | <b>29</b> |
| <b>2.1 Static variables selection</b> .....  | <b>29</b> |
| <b>2.2 Dynamic variables selection</b> .....   | <b>29</b> |
| <b>2.3 Robustness check of vaccination data</b> .....                                  | <b>30</b> |
| <b>2.4 Sensitivity analysis of prior window length for previous infection</b> .....    | <b>31</b> |
| <b>2.5 Sensitivity analysis of lags for previous infection</b> .....                   | <b>32</b> |
| <b>2.6 GAMs with reported case-incidence rate (RCIR) as the outcome variable</b> ..... | <b>33</b> |
| <b>3. Supplementary Results</b> .....  | <b>33</b> |
| <b>3.1 Models evaluation for GAMs with RCHR as outcome variable</b> .....              | <b>33</b> |
| <b>3.2 Models evaluation for GAMs with RCIR as outcome variable</b> .....              | <b>38</b> |

743

744

745


746

## 747 1. Supplementary Data

### 748 1.1 Preprocessing of genomic data

749 All genomic data were collected from GISAID [1] on October 27<sup>th</sup>, 2022. GISAID is a publicly accessible repository  
750 of dataset that sharing of genomic data on various pathogens, including influenza and COVID-19. We analyzed the  
751 available set of sequences, to determine the proportion of each variant theoretically in circulation. Specifically, we  
752 calculated the proportion of each variant for each week in each state from March 1<sup>st</sup>, 2021, to March 1<sup>st</sup>, 2022. To  
753 identify the most dominant variant for each state-week pair during the analyzed period, we labeled the state-week  
754 pairs based on the variant with the highest proportion. This enables us to track the dominant variant in each state and  
755 cluster the state-week pairs based on the most dominant variant. The assignment of state-week pairs is shown in  
756 Appendix figure S1 below:

757



758

759

760 Appendix figure S1: State-week group assignment based on the dominant variant. The x-axis represents each week,  
761 the y-axis represents each state, and the color represents the assignment of each state-week pair.

762  
763  
764  
765  
766  
767

## 768 *1.2 Variables description*

### 769 ***Outcome variable***

770 Case-hospitalization risk: In this study we used case-hospitalization risk ( $CHR_i^t$ ) as the outcome variable of interest  
771 for our model. COVID-19 case-hospitalization risk represent both the severity of COVID-19 disease at an individual  
772 level and the burden it places on the healthcare system. Case-hospitalization risk ( $CHR_i^t$ ) for each state  $i$  and week  $t$   
773 is defined as follow:

$$774 \quad CHR_i^t = \frac{H_i^t}{C_i^{t-1}},$$

775 where  $H_i^t$  is the number of hospitalizations for state  $i$  and week  $t$  and  $C_i^{t-1}$  is the number of confirmed cases for  
776 state  $i$  and week  $t - 1$ . We applied a one-week lag between reported confirmed cases and hospitalizations to account  
777 for the time between symptom onset and hospital admission [2]. Weekly state-level  $CHR_i^t$  was treated as the  
778 outcome variable in this analysis and served as an indicator for the burden of COVID-19 risk for a given time and  
779 location.

### 780 781 ***Dynamic Covariates***

782 Vaccination rate: In this analysis, the weekly cumulative COVID-19 vaccination rate is the primary variable under  
783 examination, as we hypothesize it to be a critical determinant in protecting populations against severe COVID-19  
784 disease. The completed primary series rate was chosen over the partial vaccination rate because it represents the  
785 recommended dosage by the U.S. CDC. To address the fact that vaccine eligibility was not available to all U.S.  
786 adults until April 19<sup>th</sup>, 2021, we also ran the model using the partial vaccination rate for the pre-Delta waves, and the  
787 results are consistent with the completed primary series rate (results are presented in Appendix section 2.3). As  
788 booster shots became widely available during the Omicron wave, we also include the booster vaccination rate as a  
789 covariate to investigate its potential impact on COVID-19 health outcomes. Due to errors and anomalies in the data,  
790 the vaccination data excludes West Virginia and New Hampshire, while the booster vaccination data excludes West  
791 Virginia, New Hampshire, and North Carolina. As a result, West Virginia and New Hampshire are excluded from all  
792 analyses, and North Carolina is excluded from the booster analysis for the Omicron wave.

793 Activity-related engagement level: We adapted multiple mobility-derived metrics from a previous study [3] to  
794 represent destination-specific travel behaviors and activity-related engagement levels for specific types of activities,  
795 namely gym, university, and physician visits. Specifically, the engagement levels represent the weekly number of  
796 visits to a given destination of interest per person per week. This variable allows us to compare the relative  
797 frequency of visits to each point of interest across states and to investigate their potential impact on COVID-19  
798 health outcomes. The metrics were generated based on anonymized mobility data from Safegraph [4], which tracks  
799 the number of visits to different types of destinations for a sample of the population at the census tract level in the  
800 U.S. Examples of destinations include full-service restaurants, gyms, and grocery stores. The original Safegraph  
801 dataset includes over 20 destination categories; thus, to reduce the complexity of the model we identified a smaller  
802 representative set of destinations to include as input in the final model. This was accomplished by first organizing  
803 the destination categories into six distinct destination groups based on the first two digits of the NAICS code [5],  
804 namely Retail Trade (44-45), Education Services (61), Healthcare and Social Assistance (62), Arts, Entertainment,  
805 and Recreation (71), Accommodation and Food Services (72), and Other Services (81). From each group, we  
806 selected one destination category as the representative variable for the group based on the correlations between other  
807 variables within the group (Details are documented in Appendix section 1.4). Subsequently, we conducted a model

808 selection process to identify the most appropriate subset of mobility variables from these six to be included in the  
809 final model based on concurrency and significance level (details are documented in Appendix section 2.2).

810 Previous infection rates: Several studies have demonstrated the effectiveness of previous infections against  
811 reinfections and severe COVID-19 outcomes. Studies have illustrated that individuals retain a substantial level of  
812 natural immunity for six months after infection [6–8]. To attempt to account for the role of recently acquired  
813 immunity from infection in protecting from severe disease upon reinfection in our study we generate a variable to  
814 represent the total population infected and recovered within a recent window, i.e., the total infections reported  
815 between weeks  $(t-16)$  and  $(t-4)$ , which allows for time to recover and build up immunity [9] by the time period  $t$  at  
816 which the hospitalizations are modeled, but short enough that immunity has not waned. These specific prior  
817 infections variable ( $PI_i^t$ ), requires multiple parameters, namely the length of the interval that infections are summed  
818 over and the start and end period of the window. To identify the best window and evaluate the sensitivity of our  
819 analysis to the chosen window length, start and end time, we conducted a sensitivity analysis. The time window with  
820 the largest deviance explained in the GAMs was selected for the final model, which was a three-month window  
821 ranging from 4 to 16 weeks prior to time  $t$ . Additional details of this sensitivity analysis and the results are included  
822 in Appendix section 2.4. The mathematical formulation of this metric is defined as follows:

$$PI_i^t = \frac{\sum_{j:t-16}^{t-4} C_i^j}{pop_i}$$


823 where  $PI_i^t$  represents cumulative infection rate for state  $i$  from 16 to 4 weeks prior of week  $t$ ,  $C_i^j$  is the weekly  
824 confirmed cases for state  $i$  at week  $j$ , and  $pop_i$  is the population for state  $i$ . The sum in the numerator defines the  
825 summation of  $C_i^j$  for the  $t - 16$  to  $t - 4$  weeks prior to  $t$ .

826 Government policy: The stringency and timing of implementing government policies to mitigate the impacts of  
827 COVID-19, such as school closure, cancellation of public events, and international travel controls, are associated  
828 with different measures of epidemic severity [10]. We selected the government response index from Oxford  
829 Coronavirus Government Response Tracker (OxCGRT) [11] as our indicator for government policy. The index  
830 tracks the diversity of government responses across various policies, ranging from containment measures and  
831 closures to healthcare systems, vaccination strategies, and economic policies. This index reflects the government's  
832 response level with a number ranging from 0 to 100, the larger the number, the more substantial the response. It is  
833 available for all 50 states in the U.S. at a weekly timescale for the entire period of analysis.

834 Weekly testing rate: The weekly testing rates were included in the model as a potential confounding factor for  
835 multiple reasons. Firstly, it represents a proxy input feature to capture the level of healthcare infrastructure available  
836 to a population. Second, it directly impacts the case-hospitalization risk through the denominator (i.e., total reported  
837 cases), as the number of reported cases in a region is a direct function of local testing availability, thus increased  
838 testing will lead to higher reported case rates, and lower case-hospitalization risk. For example, in two locations with  
839 the same true case-hospitalization risk (e.g., the likelihood of a COVID-19 infection needing admittance is equal), a  
840 location with twice as much testing will detect more cases, and therefore appear to have a lower case-hospitalization  
841 risk. Third, increased testing can lead to more cases being identified, and thus impact people's awareness and  
842 behavior during an outbreak. For these reasons testing rate is included as a potential confounding factor in our model.  
843 We normalized the raw weekly total testing count by population to get the weekly testing rate.

844





845  
 846 Appendix figure S2: Visualization of dynamic variables before variable transformation (a1 to h1) and after variable  
 847 transformation (a2 to h2). For the y-axis label, the abbreviations signify the following variables: CHR: Case-  
 848 hospitalization risk, CPSR: Completed primary series rate, PI: Previous infection, GR: Government policy measure,  
 849 WTR: Weekly testing rate, UV: University visits, GV: Gym visits, PV: Physician visits.

850  
 851  
 852  
 853  
 854  
 855  
 856  
 857  
 858  
 859  
 860  
 861  
 862  
 863  
 864



865 **Static Covariates**

866 Appendix table S1: Full list of static variables.

| Variable name              | Variable description  | source |
|----------------------------|---|--------|
| Static variables           |   |        |
| Black proportion           | The proportion of the population identified as non-Hispanic Blacks.   | [13]   |
| Medicaid spending          | Total Medicaid spending in kilo for each state normalized by the population.  | [14]   |
| Healthcare spending        | Total Healthcare spending in kilo for each state normalized by the population.  | [15]   |
| Poverty rate               | Percentage of population living below poverty line.   | [16]   |
| Social Vulnerability Index | The Social Vulnerability Index utilizes data from the U.S. Census to assess the relative level of social vulnerability in each census tract. By analyzing 14 social factors, the SVI categorizes tracts into four closely interrelated themes and then aggregates them as a single indicator of social vulnerability. | [17]   |
| HAQI                       | IHME's healthcare access and quality index.   | [18]   |
| Republican voters          | Percentage of a state's voters who voted for the 2020 Republican presidential candidate.  | [19]   |
| Adults at high risk        | The proportion of the population over 18 years old is at high risk of serious illness if infected with Coronavirus.   | [20]   |
| Proportion over 65         | Proportion of population age 65 and older.  | [20]   |

867  
868  
869  
870  
871  
872  
873  
874  
875  
876  
877  
878  
879  
880  
881  
882  
883  
884  
885  
886  
887  
888  
889  
890

891  
892  
893  
894  
895  
896  
897  
898  
899  
900  
901  
902

*1.3 Preprocessing of mobility data*

The 21 mobility destination categories from Safegraph were organized into six distinct industry groups based on the NAICS code. The relevant groups per the NAICS code are Retail Trade (44-45), Education Services (61), Healthcare and Social Assistance (62), Arts, Entertainment, and Recreation (71), Accommodation and Food Services (72), and Other Services (81).<sup>2</sup> The details of generating visits to each POI are documented in previous publication.

Appendix table S2: Description of each industry group and the corresponding destination categories.

| Retail Trade (44-45)            | Education Services (61)    | Healthcare and Social Assistance (62) | Arts, Entertainment, and Recreation (71) | Accommodation and Food Services (72) | Other Services (81)              |
|---------------------------------|----------------------------|---------------------------------------|--|--------------------------------------|----------------------------------|
| Automotive Store (441310)       | Elementary School (611110) | Office of Physician (621111)          | Parks (712190)                           | Hotels (721110)                      | Religious Organizations (813100) |
| Hardware Store (444130)         | University (611310)        | Child Day Care (624410)               | Gym (713940)                             | Full-Service Restaurant (722511)     |                                  |
| Grocery Store (445110)          |                            |                                       |  | Cafes, Snacks, Bars (722515)         |                                  |
| Convenience Store (445120)      |                            |                                       |  | Limited-Service Restaurant (722513)  |                                  |
| Pharmacies (446110)             |                            |                                       |  |                                      |                                  |
| Gas Station (447110)            |                            |                                       |  |                                      |                                  |
| Sporting Goods Store (451110)   |                            |                                       |  |                                      |                                  |
| Department Store (452210)       |                            |                                       |  |                                      |                                  |
| Other General Store (452319)    |                            |                                       |  |                                      |                                  |
| Used Merchandise Store (453310) |                            |                                       |  |                                      |                                  |

903  
904  
905  
906  
907  
908  
909  
910  
911  
912

To reduce the complexity of the model, we selected one destination category as the representative variable for each industry group. For the industry groups with more than 3 destination categories, we conducted a Pearson's correlation analysis and selected the variable that had the highest correlation to the other destination categories in each group. This method selected Gas Stations and Full-Service Restaurant from the Retail Trade (44-45) and Accommodation and Food Services (72) as the representative variable for each industry group. For the Educational Services (61) and Healthcare and Social Assistance (62) groups, we selected University and Office of Physician as the representative variables based on studies that indicated SARS-CoV-2 infection severity is lower in adolescents than adults.<sup>3</sup> For the Arts, Entertainment, and Recreation (71) industry group, we selected Gym as the representative variable instead of Parks because studies have identified park use to have a minor effect on COVID-19 transmission


913 compared to other mobility destinations.<sup>4</sup> Religious Organizations was selected from the Other Services (81)  
 914 industry group because it is the only destination category present.

915 **2. Supplementary Methods**

916 *2.1 Static variables selection*

917 We selected state-level static variables that were found to have association with COVID-19 health outcomes in a  
 918 recent study [12]. These variables cover a ranging of different factors, such as socioeconomic indicators, racial  
 919 demographics, age, proxy for comorbidities, political factors, and state-level healthcare expenditures. Then, a  
 920 correlation analysis is performed within static variables to determine the suitable variables to be included in the  
 921 model. Full list of static variables included in the correlation analysis are listed in Appendix table S1.

922



923 Appendix figure S3. Pearson’s correlation heatmap between each pair of static variables.  
 924

925

926 Based on the correlation analysis, the set of static variables to be incorporated into the models was determined. We  
 927 selected the black proportion as a representative variable for the race group and the SVI as a proxy for the  
 928 vulnerable population. The poverty rate was dropped due to its high correlation with SVI. Additionally, we selected  
 929 adults at high risk as a control variable for population-level comorbidities and dropped the proportion over 65. We  
 930 also decided to include Medicaid spending over healthcare spending as the state-level proxy for healthcare  
 931 expenditures. Lastly, we dropped the HAQI and Republican voters variables due to their high correlation with the  
 932 completed primary series rate.

933

934

935

936

937 *2.2 Dynamic variables selection*

938 The GAMs fit outcome variables with smoothed independent variables, allowing the nonlinear relationships  
 939 between input and output. However, the nonlinear variables smoothing sometimes can result in concurvity issues.  
 940 Concurvity occurs when some smooth term in a model could be approximated by one or more of the other smooth  
 941 terms, leading to inaccurate estimates of the effect for given variables. In this section, we conduct model selection to

942 ensure the validity of our model and to detect and mitigate any concurrency issues that may arise, using mobility data  
 943 selected from Appendix section 1.4 and other independent variables. The significance level and the concurrency for  
 944 each variable for every model are reported in table S2 below:

945  
 946 Appendix table S3: Significance level and concurrency for all dynamic variables.

| Variable                                    | Pre-Delta wave |            | Delta wave |            | Omicron wave |            |
|---|----------------|------------|------------|------------|--------------|------------|
|   | Signif         | Concurvity | Signif     | Concurvity | Signif       | Concurvity |
| Relative completed primary series rate      | ***            | 0.71       | ***        | 0.79       | ***          | 0.81       |
| Relative previous infection rate (12 weeks) | ***            | 0.62       | ***        | 0.31       | ***          | 0.41       |
| Relative full-service restaurant rate       |                | 0.82       |            | 0.81       | *            | 0.86       |
| Relative gas station visits                 |                | 0.91       |            | 0.85       | **           | 0.89       |
| Relative religious organization visits      | ***            | 0.84       |            | 0.84       | **           | 0.87       |
| Relative gym visits                         | ***            | 0.69       | **         | 0.76       |              | 0.76       |
| Relative university visits                  | *              | 0.80       | ***        | 0.62       | ***          | 0.64       |
| Relative office of physician visits         | ***            | 0.70       |            | 0.65       | **           | 0.68       |
| Relative weekly testing rate                | ***            | 0.81       | ***        | 0.64       | ***          | 0.57       |
| Relative government response index          | ***            | 0.78       | ***        | 0.32       |              | 0.27       |

947 Significance codes: ‘\*\*\*’: 0.001, ‘\*\*’: 0.01, ‘\*’: 0.05, ‘.’: 0.1, ‘’: > 0.1.

948  
 949 The value of concurrency range from 0 to 1, the higher the concurrency the more a smooth variable can be  
 950 approximated by the smooth of other variables. Specifically, a concurrency value above 0.8 generally signals the need  
 951 for careful inspection of the model. Based on the results from table S3, we removed relative full-service restaurant,  
 952 relative gas station, and relative religious organization visits from the model. This decision was based on their lack  
 953 of significance and/or their high concurrency values. The equivalent results for selected variables are presented in  
 954 table S3.

955  
 956 Appendix table S4: Significance level and concurrency for selected variables.


| Variable                                    | Pre-Delta wave |            | Delta wave |            | Omicron wave |            |
|---|----------------|------------|------------|------------|--------------|------------|
|   | Signif         | Concurvity | Signif     | Concurvity | Signif       | Concurvity |
| Relative completed primary series rate      | ***            | 0.63       | ***        | 0.61       | ***          | 0.60       |
| Relative previous infection rate (12 weeks) | ***            | 0.59       | ***        | 0.25       | ***          | 0.35       |
| Relative gym visits                         | ***            | 0.54       |            | 0.57       |              | 0.56       |
| Relative university visits                  |                | 0.69       | ***        | 0.49       | ***          | 0.44       |
| Relative office of physician visits         | ***            | 0.66       |            | 0.60       | **           | 0.64       |
| Relative weekly testing rate                | ***            | 0.78       | ***        | 0.51       | ***          | 0.51       |
| Relative government response index          | ***            | 0.72       | ***        | 0.26       | *            | 0.23       |

957 Significance codes: ‘\*\*\*’: 0.001, ‘\*\*’: 0.01, ‘\*’: 0.05, ‘.’: 0.1, ‘’: > 0.1.

958  
 959 The results from table S4 reveal that each variable exhibits a concurrency value below 0.8 and is significant in at least  
 960 one out of three models.

961  
 962 *2.3 Robustness check of vaccination data*

963 We selected the completed primary series rate as the main vaccination variable in the main analysis. To assess the  
 964 robustness and validity of our findings, we conducted additional analyses using different vaccination data  
 965 (completed primary series rate, and partial vaccination rate) and varying starting dates (March 8<sup>th</sup>, 2021, and April  
 966 19<sup>th</sup>, 2021) for the analysis. We applied our sensitivity analysis to Model Pre-Delta-RCHR, as it is the only ones that  
 967 could be affected by the analysis. The results of four different combination of vaccination data and starting date for  
 968 Model Pre-Delta-RCHR are shown in Appendix figure S4 below:




969  
970 Appendix figure S4: Robustness check of vaccination rate with different vaccination data and varying starting date  
971 for Model Pre-Delta-RCHR.

972  
973 The finding from this robustness check demonstrated a strong and consistent impact of vaccination, independent of  
974 the chosen vaccination data or the starting date of the analysis. This consistency suggests the robustness of our  
975 results and highlights the robustness of the completed primary series rate as the main vaccination variable.

976  
977 *2.4 Sensitivity analysis of prior window length for previous infection*

978 In this section, we presented a sensitivity analysis to assess the impact of the prior window length for the previous  
979 infection on our analysis. To ensure our results are robust, we fixed all other covariates and a lag of four weeks for  
980 previous infections while varying the prior window length for previous infections from 12 to 24 weeks. The results  
981 of this sensitivity analysis for each model are shown below:




982

983 Appendix figure S5: Comparison of accumulated local effects of the previous infection rate for Model Pre-Delta-  
984 RCHR (a), Delta-RCHR (b), and Omicron-RCHR (c) with different prior window lengths (12, 16, 20 and 24 weeks).

985  
986  
987  
988  
989  
990  
991  
992  
993  
994  
995  
996  
997

### 998 2.5 Sensitivity analysis of lags for previous infection

999 This section presents a sensitivity analysis to assess the impact of the prior window length for the previous infection  
1000 on our analysis. To ensure our results are robust, we fixed all other covariates and a prior window length of 12  
1001 weeks for previous infections while varying the lag for previous infections from 4 to 16 weeks. The results of this  
1002 sensitivity analysis for each model are shown below:  
1003



1004  
1005 Appendix figure S6: Comparison of the accumulated local effects of the previous infection rate for Model Pre-Delta-  
1006 RCHR (a), Delta-RCHR (b) and Omicron-RCHR (c) with different lags (4, 8, 12, and 16 weeks).

1007  
1008  
1009  
1010  
1011  
1012



1013

1014 *2.6 GAMs with reported case-incidence rate (RCIR) as the outcome variable*

1015 These GAMs share the same framework as Model Pre-Delta-RCHR, Delta-RCHR, and Omicron-RCHR, while the  
1016 outcome variable is the reported case-incidence rate (RCIR). To account for the sequential process leading to  
1017 infections, all lags between dynamic covariates and RCIR have been reduced by one week. These three GAMs have  
1018 the form:

1019

$$\begin{aligned} RCIR_i^t &\sim \text{Gamma}(\mu, \phi) \\ \log(\mu) &= \alpha + f_1(RCPSR_i^{t-1}) + f_2(RWTR_i^{t-1}) + f_3(RGV_i^{t-1}) + f_4(RPV_i^{t-1}) \\ &+ f_5(RUV_i^{t-1}) + f_6(RGP_i^{t-1}) + f_7(RPI_i^t) + \beta_1(\text{Black proportion}) + \beta_2(SVI) + \beta_3(\text{Proportion of adults at high risk}) + \beta_4(\text{Medicaid spending}) \end{aligned} \quad (S1)$$

1020

1021 Where  $\alpha$  represents the intercept,  $\beta_i$  represent the parametric coefficients of each static variable, and  $f_i$  are spline  
1022 smooth functions of the relative dynamic variables. Additionally, a model is constructed for the Omicron wave,  
1023 incorporating an interaction between completed primary series and booster rate (Omicron-Booster-RCIR). The  
1024 model Omicron-Booster-RCIR has the form:

1025

$$\begin{aligned} RCIR_i^t &\sim \text{Gamma}(\mu, \phi) \\ \log(\mu) &= \alpha + f_1(RCPSR_i^{t-1}, RBR_i^{t-1}) + f_2(RWTR_i^{t-1}) + f_3(RGV_i^{t-1}) + f_4(RPV_i^{t-1}) \\ &+ f_5(RUV_i^{t-1}) + f_6(RGP_i^{t-1}) + f_7(RPI_i^t) + \beta_1(\text{Black proportion}) + \beta_2(SVI) + \beta_3(\text{Proportion of adults at high risk}) + \beta_4(\text{Medicaid spending}) \end{aligned} \quad (S2)$$

1026

1027 Where  $f_1$  represent a smooth interaction function between  $RCPSR_i^{t-2}$  and  $RBR_i^{t-2}$ . For all the mentioned models  
1028 above, the weekly state-level RCHR is assumed to follow a Gamma distribution with a log link. This choice of the  
1029 Gamma family accounts for the positively skewed distribution of the outcome variable. We use thin plate regression  
1030 splines as the smoothing basis for all  $f_i$  and set the basis dimension to three to maximize the interpretability of the  
1031 models.

1032

1033

1034

1035

1036

1037

1038


1039

1040


1041 **3. Supplementary Results**

1042 *3.1 Models evaluation for GAMs with RCHR as outcome variable*

1043




1044  
1045 Appendix figure S7: Model diagnostic plots for Model Pre-Delta-RCHR. The correlation coefficient between fitted  
1046 RCHR and predicted RCHR is 0.78.  
1047




1048  
1049 Appendix figure S8: Model diagnostic plots for Model Delta-RCHR. The correlation coefficient between fitted  
1050 RCHR and predicted RCHR is 0.67.  
1051

1052  
1053  
1054  
1055  
1056  
1057  
1058  
1059  
1060  
1061  
1062  
1063  
1064  
1065  
1066  
1067  
1068  
1069  
1070  
1071



1072  
1073  
1074  
1075  
1076  
1077  
1078  
1079  
1080  
1081  
1082  
1083  
1084  
1085  
1086  
1087  
1088  
1089  
1090  
1091  
1092  
1093  
1094  
1095

Appendix figure S9: Model diagnostic plots for Model Omicron-RCHR. The correlation coefficient between fitted RCHR and predicted RCHR is 0.81.




1096  
1097  
1098  
1099  
1100  
1101  
1102  
1103  
1104  
1105  
1106  
1107  
1108  
1109  
1110  
1111  
1112  
1113  
1114  
1115  
1116  
1117

Appendix figure S10: Model diagnostic plots for Model Omicron-Booster-RCHR. The correlation coefficient between fitted RCHR and predicted RCHR is 0.83.




1118 3.2 Models evaluation for GAMs with RCIR as outcome variable



1119 Appendix figure S11: Model diagnostic plots for Model Pre-Delta-RCIR. The correlation coefficient between fitted  
1120 RCHR and predicted RCHR is 0.57.  
1121


1122  
1123  
1124  
1125  
1126  
1127  
1128  
1129  
1130  
1131  
1132  
1133  
1134  
1135  
1136  
1137  
1138  
1139  
1140  
1141



1142  
1143 Appendix figure S12: Model diagnostic plots for Model Delta-RCIR. The correlation coefficient between fitted  
1144 RCHR and predicted RCHR is 0.61.  
1145


1146  
1147  
1148  
1149  
1150  
1151  
1152  
1153  
1154  
1155  
1156  
1157  
1158  
1159  
1160  
1161  
1162  
1163

1164  
1165



1166  
1167 Appendix figure S13: Model diagnostic plots for Model Omicron-RCIR. The correlation coefficient between fitted  
1168 RCHR and predicted RCHR is 0.43.  
1169  
1170  
1171  
1172  
1173  
1174  
1175  
1176  
1177  
1178  
1179  
1180  
1181  
1182  
1183  
1184  
1185  
1186  
1187

1188  
1189



1190  
1191 Appendix figure S14: Model diagnostic plots for Model Omicron-Booster-RCIR. The correlation coefficient  
1192 between fitted RCHR and predicted RCHR is 0.44.

1193  
1194  
1195  
1196  
1197  
1198  
1199  
1200  
1201  
1202  
1203  
1204  
1205  
1206  
1207  
1208  
1209  
1210  
1211

## 1212 Reference

- 1213 [1] Khare S, Gurry C, Freitas L, Schultz MB, Bach G, Diallo A, et al. GISAID's role in pandemic response.  
1214 China CDC Wkly 2021;3:1049.
- 1215 [2] Faes C, Abrams S, Van Beckhoven D, Meyfroidt G, Vlieghe E, Hens N, et al. Time between symptom onset,  
1216 hospitalisation and recovery or death: statistical analysis of Belgian COVID-19 patients. *Int J Environ Res*  
1217 *Public Health* 2020;17:7560.
- 1218 [3] Du H, Dong E, Badr HS, Petrone ME, Grubaugh ND, Gardner LM. Incorporating variant frequencies data into  
1219 short-term forecasting for COVID-19 cases and deaths in the USA: a deep learning approach. *EBioMedicine*  
1220 2023;89:104482. <https://doi.org/10.1016/j.ebiom.2023.104482>.
- 1221 [4] Places Data Curated for Accurate Geospatial Analytics | SafeGraph n.d. <https://www.safegraph.com> (accessed  
1222 January 13, 2023).
- 1223 [5] NAICS & SIC Identification Tools. NAICS Assoc n.d. <https://www.naics.com/search/> (accessed April 6, 2023).
- 1224 [6] Altarawneh HN, Chemaitelly H, Ayoub HH, Tang P, Hasan MR, Yassine HM, et al. Effects of Previous  
1225 Infection and Vaccination on Symptomatic Omicron Infections. *N Engl J Med* 2022;387:21–34.  
1226 <https://doi.org/10.1056/NEJMoa2203965>.
- 1227 [7] Goldberg Y, Mandel M, Bar-On YM, Bodenheimer O, Freedman LS, Ash N, et al. Protection and Waning of  
1228 Natural and Hybrid Immunity to SARS-CoV-2. *N Engl J Med* 2022;386:2201–12.  
1229 <https://doi.org/10.1056/NEJMoa2118946>.
- 1230 [8] Bobrovitz N, Ware H, Ma X, Li Z, Hosseini R, Cao C, et al. Protective effectiveness of previous SARS-CoV-2  
1231 infection and hybrid immunity against the omicron variant and severe disease: a systematic review and meta-  
1232 regression. *Lancet Infect Dis* 2023;23:556–67. [https://doi.org/10.1016/S1473-3099\(22\)00801-5](https://doi.org/10.1016/S1473-3099(22)00801-5).
- 1233 [9] Abraham SA, Tessema M, Defar A, Hussen A, Ejeta E, Demoz G, et al. Time to recovery and its predictors  
1234 among adults hospitalized with COVID-19: A prospective cohort study in Ethiopia. *PLOS ONE*  
1235 2020;15:e0244269. <https://doi.org/10.1371/journal.pone.0244269>.
- 1236 [10] Haug N, Geyrhofer L, Londei A, Dervic E, Desvars-Larrive A, Loreto V, et al. Ranking the effectiveness of  
1237 worldwide COVID-19 government interventions. *Nat Hum Behav* 2020;4:1303–12.
- 1238 [11] Hale T, Webster S, Petherick A, Phillips T, Kira B. Oxford COVID-19 government response tracker  
1239 (OxCGRT). *Last Updat* 2020;8:30.
- 1240 [12] Bollyky TJ, Castro E, Aravkin AY, Bhangdia K, Dalos J, Hulland EN, et al. Assessing COVID-19 pandemic  
1241 policies and behaviours and their economic and educational trade-offs across US states from Jan 1, 2020, to  
1242 July 31, 2022: an observational analysis. *The Lancet* 2023;S0140673623004610.  
1243 [https://doi.org/10.1016/S0140-6736\(23\)00461-0](https://doi.org/10.1016/S0140-6736(23)00461-0).
- 1244 [13] Bureau UC. State Population by Characteristics: 2010-2019. *CensusGov* n.d.  
1245 <https://www.census.gov/data/datasets/time-series/demo/popest/2010s-state-detail.html> (accessed April 9,  
1246 2023).
- 1247 [14] Total Medicaid Spending. KFF 2022. <https://www.kff.org/medicaid/state-indicator/total-medicaid-spending/>  
1248 (accessed February 13, 2023).
- 1249 [15] Health Care Expenditures by State of Residence (in millions). KFF 2022. [https://www.kff.org/other/state-  
1250 indicator/health-care-expenditures-by-state-of-residence-in-millions/](https://www.kff.org/other/state-indicator/health-care-expenditures-by-state-of-residence-in-millions/) (accessed February 13, 2023).
- 1251 [16] Poverty Rate by Race/Ethnicity. KFF 2022. [https://www.kff.org/other/state-indicator/poverty-rate-by-  
1252 raceethnicity/](https://www.kff.org/other/state-indicator/poverty-rate-by-raceethnicity/) (accessed February 13, 2023).
- 1253 [17] CDC/ATSDR SVI Data and Documentation Download | Place and Health | ATSDR 2022.  
1254 [https://www.atsdr.cdc.gov/placeandhealth/svi/data\\_documentation\\_download.html](https://www.atsdr.cdc.gov/placeandhealth/svi/data_documentation_download.html) (accessed February 13,  
1255 2023).
- 1256 [18] Global Burden of Disease (GBD). *Inst Health Metr Eval* 2014. <https://www.healthdata.org/gbd> (accessed  
1257 April 9, 2023).
- 1258 [19] Harvard Dataverse. *Harv Libr* n.d. <https://library.harvard.edu/services-tools/harvard-dataverse> (accessed April  
1259 9, 2023).
- 1260 [20] Adults at Higher Risk of Serious Illness if Infected with Coronavirus. KFF 2020.  
1261 <https://www.kff.org/other/state-indicator/adults-at-higher-risk-of-serious-illness-if-infected-with-coronavirus/>  
1262 (accessed February 13, 2023).

1263

1264



1265

1266

1267